Hot Pursuit     30-Aug-22
ICRA appoints Venkatesh Viswanathan as CFO
ICRA said that its board of directors has approved the appointment of Venkatesh Viswanathan as a group chief financial officer (CFO) and key managerial personnel of ICRA, effective from 30 August 2022.

The company has designated Viswanathan as the chief investor relations officer of the company.

Further, the company said that Amit Kumar Gupta, the chief financial officer of the company, appointed for an interim period, has stepped down as chief financial officer. He will continue to hold his current key managerial position of general counsel of the company.

Venkatesh Viswanathan has over two decades of experience in finance, accounts, audit, taxation, financial risks and controls, treasury, and internal audit. Prior to joining ICRA, he worked with CRISIL as the CFO for the Ratings business and Senior Director - Group Finance. His previous stints were with IT Nation (India) and the National Stock Exchange of India.

In the past, he has worked on enabling successful regulatory transitions, mergers, acquisitions, hive-offs, financial due diligences, tax structuring, and cost management. He has also led finance teams in various automation initiatives to work towards sustainable business growth.

In January this year, Vipul Agarwal, ICRA's former CFO, had resigned from his postion in the company to pursue external career opportunities.

Following this, the board of ICRA had approved the appointment of Amit Kumar Gupta as a chief financial officer of the company for an interim period.

ICRA (formerly Investment Information and Credit Rating Agency of India) was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment information and credit rating agency. The ultimate parent company of international Credit Rating Agency Moody's Investors Service is the indirect largest shareholder of ICRA.

On a consolidated basis, the company's operating income increased by 15.8% to Rs. 92.5 crore in Q1 FY23 over Q1 FY22. Consolidated PAT, however, declined by 11.1% YoY to Rs 21.6 crore during the period under review.

The scrip rose 0.81% to currently trade at Rs 3737.10 on the BSE.

On a year-to-date (YTD) basis, the stock has gained 10.86% while the benchmark Sensex has added 0.36% during the same period.

Previous News
  ICRA
 ( Results - Analysis 29-Jan-26   08:27 )
  Board of ICRA recommends final dividend
 ( Corporate News - 25-May-23   11:25 )
  ICRA to discuss results
 ( Corporate News - 12-Jul-23   10:29 )
  ICRA consolidated net profit declines 7.64% in the December 2025 quarter
 ( Results - Announcements 29-Jan-26   07:36 )
  ICRA to table results
 ( Corporate News - 28-Sep-23   11:58 )
  ICRA to declare Quarterly Result
 ( Corporate News - 23-Jan-25   11:26 )
  ICRA arm applies to SEBI for ESG rating provider license
 ( Corporate News - 28-Sep-23   19:18 )
  Board of ICRA recommends special dividend
 ( Corporate News - 25-May-23   11:25 )
  Volumes spurt at Indiabulls Real Estate Ltd counter
 ( Hot Pursuit - 20-Mar-20   14:30 )
  ICRA schedules board meeting
 ( Corporate News - 05-Jul-24   10:33 )
  Volumes soar at Bharat Dynamics Ltd counter
 ( Hot Pursuit - 30-Jun-20   14:30 )
Other Stories
  Lemon Tree Hotels signs new property in Gujarat
  20-Apr-26   07:14
  Marsons bags Rs 15-cr order from Inox Solar
  18-Apr-26   18:35
  Texmaco Rail & Engineering bags Rs 3-cr order from Modern Coach Factory
  18-Apr-26   17:36
  ICICI Bank records PAT of Rs 13,702 crore in Q4; board OKs dividend of Rs 12/share
  18-Apr-26   17:20
  HDFC Bank Q4 PAT rises 9% YoY to Rs 19,221 crore; declares dividend of Rs 13/share
  18-Apr-26   17:17
  Interarch Building Solutions secures Rs 60-cr order
  18-Apr-26   15:29
  Yes Bank Q4 PAT climbs 45% YoY to Rs 1,068 cr
  18-Apr-26   14:57
  Cipla's manufacturing facility in Goa gets two observations in Form 483 from US FDA
  18-Apr-26   14:20
  UltraTech Cement raises total cement production capacity in India to 200.1 MTPA
  18-Apr-26   14:16
  Lupin's New Jersey-based facility gets Form-483 with three observations from US FDA
  18-Apr-26   12:27
Back Top